TET

Epitor Therapeutics Unveils CasNano: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
Donnerstag, Mai 9, 2024
Dicarboxylic acid, Disorder, CRISPR, Cas, RNA, Cell, AAV, DNA, TET, Demethylation, Gene, Society, Annual general meeting, Therapy, Biotechnology

NEW YORK, May 9, 2024 /PRNewswire/ -- Epitor Therapeutics, a biotechnology pioneer in epigenetic editing, announces the creation of CasNano, a groundbreaking ultracompact Cas protein.

Key Points: 
  • NEW YORK, May 9, 2024 /PRNewswire/ -- Epitor Therapeutics, a biotechnology pioneer in epigenetic editing, announces the creation of CasNano, a groundbreaking ultracompact Cas protein.
  • The company unveiled new data during the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, showcasing over a 20-fold improvement in targeting efficiency via directed evolution of CasNano and innovative re-engineering of the tracrRNA component of the guide RNA.
  • "In addition to its nuclease activity, CasNano can efficiently demethylate, methylate, and activate target genes when catalytically deactivated, with protein effectors attached.
  • "CasNano is 70% smaller than spCas9 and has been engineered to optimize DNA targeting," added Epitor CEO, Dr. Megan McGill.

Tectum Claims the Title of the Fastest Layer 1 Blockchain and Process 3.5 Million Transactions Per Second in its TPS Test Final Phase

Retrieved on: 
Donnerstag, März 14, 2024
TPS, Blockchain, History, Exercise, TET, Cryptocurrency

The update comes after the final phase of a series of live tests to show how well the blockchain can process transactions.

Key Points: 
  • The update comes after the final phase of a series of live tests to show how well the blockchain can process transactions.
  • It is unsurprising that several blockchains have been vying for the title of being the fastest blockchain in the world.
  • The Tectum TPS test final phase lasted well over one hour, with the team conducting over 50 million transactions.
  • However, Tectum, the fastest layer 1 blockchain, was able to set a new record while running this test.

Gateway to Asia: Tectum Emission Token ($TET) Set to Shine on Gate.io With New CEX Listing

Retrieved on: 
Montag, März 4, 2024
ICO, TET, KYC, Partnership, Cryptocurrency

This listing is a significant milestone in the company's plan to extend into the Asian market.

Key Points: 
  • This listing is a significant milestone in the company's plan to extend into the Asian market.
  • The blockchain firm recognizes that a significant portion of its community is from this part of the world.
  • Tectum Emission Token will be listed on the Gate.io Exchange by 6:00 AM on Tuesday, the 5th of March 2024.
  • Since this is a listing and not an ICO, the market will determine the price of each unit of TET.

Tectum Invites Early Investors to be Part of the Future By Joining the $TET Listing on Bitget

Retrieved on: 
Montag, August 21, 2023
Bitcoin, Ethereum, Crypto, T12, QR code, Blockchain, TEC, ETH, Softnotes, Commercial software, Interest, USDT, QR, Paper, BTC, TET, Cryptocurrency, Mail, Bitget, Midbrain

Tectum is on a mission to change how people transact and is already incorporating how people do business.

Key Points: 
  • Tectum is on a mission to change how people transact and is already incorporating how people do business.
  • Unlike the competition, Tectum is more than just a blockchain enterprise with a cryptocurrency.
  • Instead of the regular transaction process that is limited to on-chain transfer of tokens, tectum utilizes SoftNote Bills.
  • $TET, which also stands for Tectum Emission Token, is the native cryptocurrency of the Tectum blockchain.

$TET Listing Soars as SoftNote Introduces Live Staking and Bitcoin SoftNote System

Retrieved on: 
Montag, Juli 10, 2023
Blockchain, TEC, Life, Softnotes, Privacy, Commercial software, ATH, Traction, Growth, Ecosystem, DEX, TET, ROI, APY, Cryptocurrency, Online shopping, Bitcoin

Powered by Tectum, SoftNote introduces a fully backed and redeemable cash system, enabling seamless real-world transactions and rewarding users in the process.

Key Points: 
  • Powered by Tectum, SoftNote introduces a fully backed and redeemable cash system, enabling seamless real-world transactions and rewarding users in the process.
  • The SoftNote system offers simplicity, security, and privacy, making it an ideal solution for Bitcoin scaling.
  • With a focus on enhancing user experience and expanding its ecosystem, SoftNote introduces live staking opportunities, the launch of the Bitcoin SoftNote system, and an ongoing airdrop campaign.
  • SoftNote proudly launches the Bitcoin SoftNote system, bringing unprecedented scalability and efficiency to Bitcoin transactions.

Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility

Retrieved on: 
Dienstag, Oktober 18, 2022
Melanoma, SMR, GM, Vaccination, OSE, Population, Neoplasm, Conference, CD4, International Conference on Population and Development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Phenotype, TMB, Cancer, II, Food, Immune system, Company, TET, Nivolumab, Society, Melanoma Research, CEO, Immunotherapy, Safety, Ipilimumab, Survival, PD-L1, FDA, Lymphocyte, Reverse transcriptase, Medical imaging, Pharmaceutical industry, Birth control, Pembrolizumab, Biomarker

The analyses showed robust responses in patients treated with the combination of UV1 and pembrolizumab, regardless of patients PD-L1 status.

Key Points: 
  • The analyses showed robust responses in patients treated with the combination of UV1 and pembrolizumab, regardless of patients PD-L1 status.
  • This indicates a potential broad applicability for UV1 as a combination therapy to anti-PD1 checkpoint inhibitors in the real-world setting, said Jens Bjrheim, Chief Medical Officer at Ultimovacs.
  • These results provide a solid foundation for Ultimovacs extensive program of five randomized phase II trials of UV1 in different cancer indications, including malignant melanoma.
  • Ultimovacs lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth.

Treatment of Severe Heart Failure - AI: FineHeart Strengthens Its Management Team in the Run up to the ICOMS FLOWMAKER® First-In-Human Trials

Retrieved on: 
Donnerstag, Oktober 13, 2022
Medical Devices, Health, Other Health, Clinical Trials, Cardiology, Biotechnology, Union, Disease, CSO, Manufacturing operations, EMEA, MS, PRIMA, Central Region, Mathematics, Materials science, Cardiology, Patient, Institut national des sciences appliquées de Lyon, Investor, Engineering, Irdi Rapaj, GE Healthcare, Materials Science and Engineering, IAE, Feminization, CRT, École Polytechnique, TET, Heart failure, CEO, Business administration, Zimmer Biomet, Medical device, Doctor of Philosophy

Each of them has been captivated by the technological and clinical progress that the ICOMS FLOWMAKER represents.

Key Points: 
  • Each of them has been captivated by the technological and clinical progress that the ICOMS FLOWMAKER represents.
  • Before joining FineHeart, Guillaume was Technical and R&D Director at Pixium Vision for more than 9 years.
  • The ICOMS FLOWMAKER has everything it takes to change the lives of patients with severe heart failure, a disease impacting such a large number of people."
  • FineHeart is a medical device company that is developing its innovative ground-breaking product, ICOMS FLOWMAKER, with the potential to treat 200,000 patients with severe heart failure each year.

Tectum announces its future TET token listing on the Bitmart Exchange scheduled for 4Q22.

Retrieved on: 
Montag, September 26, 2022
Softnotes, DTL, Token, TET, Ecosystem, GLOBE, POS, Cryptocurrency, Midbrain

It is a distributed ledger protocol (DTL) platform whose ecosystem comprises the Tectum blockchain, the Tectum Wallet, the Tectum Token (TET) , the Tectum SoftNote, and the 3FA authenticator app.

Key Points: 
  • It is a distributed ledger protocol (DTL) platform whose ecosystem comprises the Tectum blockchain, the Tectum Wallet, the Tectum Token (TET) , the Tectum SoftNote, and the 3FA authenticator app.
  • This great end-to-end multi-product ecosystem called Tectum provides users with speed and security and gives POS and microtransaction entities a powerful crypto adoption tool; the SoftNote.
  • The user of TET plays a distinctive role in determining the successful outcome of their TET purchase.
  • The TET token is the gateway for people to participate and earn rewards based on their individual effort and involvement in the Tectum ecosystem.

Treatment of Severe Heart Failure - AI

Retrieved on: 
Mittwoch, September 7, 2022
Health, Medical Devices, Other Science, General Health, Research, Science, Cardiology, Patient safety, ISO, CEO, Heart failure, BSI, Compliance, Certification, TET, Industry, Patient, Medical device, Health, Medical Devices, Other Science, General Health, Research, Science, Cardiology

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification.

Key Points: 
  • FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification.
  • The whole team is extremely proud to have accomplished this crucial step in the development of the ICOMS FLOWMAKER.
  • Our goal is to allow patients suffering from severe heart failure to return to a normal life, thanks to our device for which First In Human trials are scheduled to begin next year," declared Arnaud Mascarell, CEO & co-founder of FineHeart.
  • The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Global Isocitrate Dehydrogenase (IDH) inhibitors Pipeline Research Report 2022 Featuring Bayer, Agios Pharma, Daiichi Sankyo, & Ohm Oncology - ResearchAndMarkets.com

Retrieved on: 
Freitag, Juli 29, 2022
Pharmaceutical, Health, Clinical Trials, III, Isocitrate dehydrogenase, INDIGO, Route, Enzyme, TCA, Discovery, IDH, IDH2, News, Clinical trial, Agios Pharmaceuticals, Administration, AML, IDH1, Patient, Acute myeloid leukemia, Therapy, Mutation, Route of administration, II, Pharmaceutical industry, TET

The "Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Isocitrate Dehydrogenase (IDH) inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Isocitrate Dehydrogenase (IDH) inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Isocitrate Dehydrogenase (IDH) inhibitors drugs segregated based on following parameters that define the scope of the report.
  • Isocitrate Dehydrogenase (IDH) inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.